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Fibronectin (FN) was detected on thioglycollate-induced mouse peritoneal macrophages by binding the izSI-labeled 
F(ab’), fragment of rabbit anti-human plasma fibronectin. The cell surface fibronectin (sFN) was removed from the sur- 
face of the macrophage monolayer by limited trypsinization. After trypsinization, binding of 12sI-labeled plasma fibro- 
nectin CZ51-pFN) to the macrophage monolayer was increased, suggesting that the FN receptor covered with sFN was 
exposed by trypsinization without destroying the receptor activity. The amounts of saturation binding of iZ51-pFN to 
the macrophage monolayers before and after trypsinization were about 2.4 and 6.3 pg per 106 cells, respectively, indicating 
that the macrophage monolayer has the capacity of binding 6.3 Fg FN per 106 cells, and the FN receptor equivalent 
to about 4 pg pFN per l(P cells is covered with sFN. 
Fibronectin; Fibronectin receptor; Trypsinization; (Macrophage) 
1. INTRODUCTION 
Fibronectin, an adhesive glycoprotein found on 
the surface of many types of cells and in ex- 
tracellular matrices and plasma, affects various 
cell behaviors such as cell adhesion, cell migration, 
and embryonic cell differentiation [l-3]. 
Plasma fibronectin is known to show biological 
activities on phagocytic cells of the reticuloen- 
dothelial system [4]. pFN promotes attachment of 
human monocytes to gelatin-coated substrate, and 
attachment of gelatin-coated particulate material 
to the cell monolayers [S]. It also promotes uptake 
of gelatin-coated particles by rat peritoneal 
macrophages [6,7]. Furthermore, substrate-bound 
pFN stimulates human monocytes [8] or cultured 
human monocytes [9,10] to promote opsonin (IgG 
or C3)-dependent phagocytosis of erythrocytes. 
Binding of the particle- or substrate-bound pFN to 
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the FN receptor on the phagocytes has been sup- 
posed to cause these biological effects [S-lo]. 
On the other hand, little attention has been paid 
to FN present on the surface of phagocytes. It was 
demonstrated that macrophages express FN on the 
cell surface [ 11,121, while monocytes only express 
slightly after in vitro long-term culture [ 131. 
Although the cell surface FN (sFN) of 
macrophages appears to play a regulatory role in a 
macrophage function [12], no information on the 
quantity of sFN of macrophages is available. To 
investigate the role played by sFN as well as by ex- 
tracellular FN in macrophage function, quan- 
titative analysis of sFN and the capacity of the cells 
to bind FN is important. 
In this study, we have determined the amount of 
sFN and the FN-binding capacity of thioglycollate- 
induced mouse peritoneal macrophages. 
2. MATERIALS AND METHODS 
2. I. Materials 
Trypsin (bovine pancreas, 189 U/mg) and pepsin (porcine, 
3600 U/mg) were purchased from Worthington Diagnostics, 
Freehold, New Jersey. Bovine serum albumin (BSA, crystal- 
lized and lyophilized) and soybean trypsin inhibitor (type I-S) 
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were obtained from Sigma (St. Louis, MO). BSA (fraction V) 
was the product of Miles Laboratories (Elkhart, IN). Gelatin- 
Sepharose 4B was prepared by coupling gelatin (swine skin type 
I, Sigma) with Sepharose 4B (Pharmacia Fine Chemicals, Upp- 
sala, Sweden) activated by BrCN [14]. 
2.2. Preparation of pFN, antibody to FN and its F(ab’)2 
fragment 
pFN was purified from pooled human plasma by affinity 
chromatography on gelatin-Sepharose 4B columns according to 
Engvall and Ruoslahti (151 with minor modifications. Plasma 
was passed through a plain Sepharose 4B column before the af- 
finity chromatography to remove any material which might ad- 
sorb to Sepharose gel. pFN bound to the gelatin-Sepharose 4B 
column was eluted with 4 M urea in 0.05 M Tris buffer (pH 7.5) 
after elution of loosely bound material with 1 M urea in the 
same buffer. The eluted pFN fraction was dialyzed extensively 
against 10 mM phosphate buffer/O.15 M NaCI, pH 7.2 
(phosphate-buffered saline), containing 0.02% NaNs, stored at 
4°C and used within 3 weeks. SDS-polyacrylamide gel elec- 
trophoresis [16] of the protein obtained indicated that virtually 
no proteins other than intact pFN (Mr = 220000) were present 
in the preparations. pFN concentration was determined spec- 
trophotometrically using E:% (at 280 nm) = 12.8 [7]. 
Anti-FN antibody was raised in a Japanese White rabbit us- 
ing human pFN as an antigen. The antiserum obtained was 
heat-treated at 56°C for 30 min to inactivate complements, and 
passed through a column of Sepharose 4B coupled with dia- 
lyzed pFN-free human plasma to remove rabbit antibodies reac- 
tive with human plasma proteins other than pFN. Normal 
serum obtained from the preimmune rabbit was similarly pro- 
cessed. The resultant antiserum gave a monospecific response in 
the Ouchterlony gel diffusion assay against whole human 
plasma. The antiserum as well as normal serum was further ab- 
sorbed with human erythrocytes at 4°C for 2 h. IgG was then 
isolated from the sera by ammonium sulfate precipitation 
followed by DEAE-cellulose column chromatography. F(ab’)z 
framents of anti-FN IgG and normal IgG (anti-FN F(ab’)z and 
normal F(ab’)2, respectively) were prepared by pepsin digestion 
and gel filtration on a Sephadex G-200 column. Concentration 
of F(ab ‘)z fragments was determined according to the method 
of Lowry et al. [17] using BSA as standard. 
2.3. Macrophages 
Macrophages were obtained from the peritoneal cavity of 
‘I-lo-week-old ddY male mice 4 days after an intraperitoneal 
injection of 2-3 ml of 3% thioglycollate medium (Difco 
Laboratories, Detroit, MI). Peritoneal exudate cells obtained 
were washed twice with Hanks’ balanced salt solution by cen- 
trifugation (80 x g, 10 min) at 4°C. The cells were then 
resuspended in RPM1 1640 medium (Gibco Laboratories, 
Grand Island, NY) supplemented with 20 mM Hepes (pH 7.2), 
50 U/ml penicillin and 50 fig/ml streptomycin (RPMI-Hepes 
medium) at 1 x lo6 cells per ml, and 3 ml of the cell suspension 
was plated on a 60 mm tissue culture dish (Corning Glass 
Works, Corning, NY). After incubation at 37°C for 1 h, 
nonadherent cells were removed by washing three times with 
phosphate buffered saline and the macrophage monolayers 
were subjected to the binding assay. More than 90% of the cells 
were macrophages as defined by phagocytosis of latex beads 
(0.8pm, Difco) and sheep erythrocytes sensitized with a 
subhemagglutinating dose of rabbit anti-sheep erythrocyte IgG. 
To determine the cell number of the macrophage monolayer, 
1 ml of 2% BSA (fraction V) in RPMI-Hepes medium was add- 
ed to replicate dishes, and the monolayer was scraped from the 
dish with a rubber policeman. The cells were dispersed by gentle 
pipetting, and cell number was counted under phase-contrast 
microscope. The cell number was usually 1.5-2 x lo6 per dish. 
Trypsinization of the macrophage monolayers was perform- 
ed by the incubation with l-lOO~g/ml of trypsin in RPMI- 
Hepes medium (3 ml) at 4°C for 30 min. After removal of the 
solution, soybean trypsin inhibitor (50pg/ml, 2 ml) in 
phosphate-buffered saline was added to quench the proteolysis, 
and the monolayers were washed twice with phosphate-buffered 
saline. Almost all cells remained attached to the dish under the 
conditions employed. 
2.4. Binding experiment 
Radiolabeling of pFN, anti-FN F(ab’)z, and normal F(ab’)2 
was carried out by the chloramine-T method of Hunter [18] us- 
ing Na”‘I (375 mCi/ml, carrier-free, New England Nuclear, 
Boston, MA). All the glass- and plasticwares and Sephadex 
G-25 columns for separation of the labeled pFN from free 
radioactivity were coated with 2% BSA prior to use. 
Intact and trypsinized macrophage monolayers were 
precoated with 2 ml of 2% BSA (fraction V) in RPMI-Hepes 
medium at 4°C for 30 min to prevent nonspecific adsorption of 
‘2sI-labeled proteins. The precoated macrophage monolayers 
were washed once with phosphate-buffered saline, and in- 
cubated with labeled proteins (spec. act. 10000-20000 cpm/pg) 
in RPMI-Hepes medium containing 0.5% BSA (fraction V) at 
22°C for 1 h with occasional shaking. After the incubation, the 
radioactive medium was removed, and the macrophage 
monolayers were washed 5 times with precooled phosphate- 
buffered saline. The washed monolayers were then solubilized 
in 2 ml of 4 N NaOH, and the radioactivity of the solutions was 
counted. Nonspecific adsorption of the radioactivity on the dish 
was similarly measured using the dish without macrophages, 
and this value was subtracted from the data as a blank. The 
nonspecific adsorption was usually less than 10% of the 
radioactivity bound to the monolayer dish. The data shown are 
the mean values of duplicate assays. 
3. RESULTS 
The presence of FN on macrophages was 
verified by binding the 1251-labeled F(ab’)z frag- 
ment of rabbit anti-pFN antibody (‘251-anti-FN 
F(ab’)z) to the monolayer of thioglycollate- 
induced mouse peritoneal macrophages. As shown 
in fig.lA, 12’1-anti-FN F(ab’)2 at 4pg/ml bound 
to the macrophages in proportions to the number 
of cells, while the same concentration of the r2?- 
labeled F(ab ‘)z fragment of normal rabbit IgG 
(1251-normal F(ab’)z) bound slightly. The binding 
of “‘1-anti-FN F(ab ‘)z to the cells increased 
depending on the concentration of the antibody, 
and reached a plateau at 50pg/ml antibody 
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(fig.lB). This specific 
“‘1-anti-FN F(ab ‘)2 to 
that FN is present 
macrophages. 
We, then, attempted 
and saturable binding of 
the macrophages indicates 
on the surface of the 
to estimate the amount of 
sFN as a difference in the saturation levels of pFN- 
binding to the macrophage monolayers before and 
after removal of sFN from the monolayer surface. 
To remove sFN, the macrophage monolayer was 
subjected to mild trypsinization at 4°C for 30 min. 
The amount of sFN on the monolayer, as detected 
by the binding of 12?-anti-FN F(ab’)z, was 
decreased on treatment with l-100 pug/ml of tryp- 
sin (fig.2). About 85% of sFN was removed at the 
trypsin concentration as low as 10 pg/ml. The ef- 
fect of trypsin treatment on the ability of 
macrophages to bind FN was then examined by the 
binding of ‘251-pFN to the trypsinized monolayer. 
In contrast to the binding of anti-FN-antibody, the 
binding of a fixed concentration of “‘1-pFN in- 
creased with increasing trypsin concentration 
(fig.% which suggests that the FN receptor 
covered with sFN was exposed by the removal of 
sFN. 
To make sure that the receptor activity is 
restored on removal of bound FN by trypsin, the 
following experiment was designed. The 
macrophage monolayer surface was treated with 
unlabeled pFN, trypsinized, and then i2’I-pFN 
binding was measured. As shown in table 1, 1251- 
Cell number/dish x10-5 AnwFN F(b)2 concentration (PQlmll 
Fig. 1. The presence of sFN on mouse peritoneal macrophages. 
(A) Binding of lZSI-anti-FN F(ab’)~ (0) or ‘2sI-normal F(ab’)t 
(0) to macrophage monolayers of varying cell density. 
Macrophage monolayers were incubated with i2’I-anti-FN 
F(ab’h or ‘2SI-normal F(ab’)2 at 22°C for 1 h. The 
concentration used for “‘1-anti-FN F(ab’)t and ‘251-normal 
F(ab ‘)2 was 4 pg/ml. (B) Concentration-dependent binding of 
‘251-anti-FN F(ab’)z to macrophage monolayers. Macrophage 
monolayers (2.5 x ld cells per dish) were incubated with 
increasing concentrations of t2%anti-FN F(ab’)z at 22°C for 
1 h. 
January 1989 
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Fig.2. Binding of ‘251-anti-FN F(ab ‘)2 and i2%pFN to 
trypsinized monolayers of mouse peritoneal macrophages. 
Macrophage monolayers (2.0 x lo6 cells per dish) were treated 
with 1, 10, and lOO~g/ml of trypsin in RPMI-Hepes medium 
at 4°C for 30 min. After quenching the proteolysis with trypsin 
inhibitor, the monolayers were incubated with ‘251-anti-FN 
F(ab ’ )2 (50 pg/ml) (0) or ‘251-pFN (400 pg/ml) (0) at 22°C for 
1 h. 
pFN (100 /g/ml) bound only slightly to the 
macrophage monolayer which had been treated 
with a large amount of unlabeled pFN 
(1900 ,ug/ml). However, when the unlabeled pFN- 
treated monolayer was briefly trypsinized, subse- 
quent binding of ‘251-pFN was restored to 67% of 
the ‘251-pFN binding to the monolayer not 
pretreated with unlabeled pFN. The result in- 
Table 1 
Effect of trypsinization of the macrophage monolayers 
pretreated with unlabeled pFN on the binding of ‘251-pFN 
First 
Pretreatment Bound ‘2SI-pFN 
@g per lo6 cells) 
Second 
pFN (1900 rg/ml) 
pFN (19OO/rg/ml) 
None 
None 
Trypsin (10 pg/ml) 
Trypsin (10 &ml) 
0.20 
0.54 ( 67ol0)~ 
0.82 (KW/O)~ 
a Percentage of ‘251-pFN binding 
Macrophage monolayers (1.9 x lo6 cells per dish) were 
preincubated with or without unlabeled pFN (WOO/cg/ml) in 
RPMI-Hepes medium at 22°C for 1 h. After removal of 
unbound pFN, the monolayers were treated with or without 
trypsin (lOpg/ml) as described in the legend to fig.2. The 
trypsinized or untreated monolayers were then incubated with 
‘251-pFN (lOOpg/ml) at 22°C for 1 h, and the binding of the 
radioactivity was measured 
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pFN concentration (pglml) 
Fig.3. Binding of “‘1-pFN to monolayers of mouse peritoneal 
macrophages before and after trypsinization. Macrophage 
monolayers (1.5 x lo6 cells per dish) treated with (0) or 
without (0) trypsin were incubated with increasing 
concentrations of ‘*‘I-pFN at 22°C for 1 h. Trypsinization of 
macrophage monolayers was performed as described in the 
legend to fig.2 using 10 fig/ml of trypsin. 
dicates that the FN receptor blocked with pFN can 
be exposed by trypsinization of the bound pFN 
without loss of the receptor activity. 
Concentration-dependent binding of ‘*‘I-pFN to 
the macrophage monolayers was measured before 
and after brief trypsinization. As shown in fig.3, 
the binding of ‘*‘I-pFN to the macrophage 
monolayer before trypsinization increased with the 
increase in the concentration of ‘*‘I-pFN up to 
300 pg/ml. At 4OO~g/ml, its binding rather 
decreased. The maximal binding of ‘*‘I-pFN to the 
monolayer was 2.4,ug per lo6 cells. After tryp- 
sinization of the monolayer, the binding of 1251- 
pFN reached a plateau at the ‘251-pFN concentra- 
tion above 500 pg/ml (fig.3). The maximal binding 
to the monolayer was about 6.3 pg per lo6 cells. 
This value represents the total capacity of the 
macrophage monolayer to bind FN, and the net in- 
crease in the saturation level of the 1251-pFN 
binding (approx. 4 pg pFN per lo6 cells) is likely to 
represent he amount of sFN removed by trypsin 
from the monolayer surface, which approximately 
corresponds to the total sFN present on the 
monolayer surface. 
4. DISCUSSION 
Recent progress in the research on FN has 
revealed that FN interacts with cells through its 
cell-binding domain containing the tripeptide Arg- 
Gly-Asp (RGD) [ 19,201. Cell surface FN receptors 
have also been characterized and identified as an 
140 kDa glycoprotein complex using cell surface- 
directed monoclonal antibodies which inhibit cell 
adhesion to FN-coated substrata [21-251 and the 
synthetic peptides containing the RGD sequence 
[26]. Furthermore, it has been shown that many 
adhesive proteins contain the RGD sequence, and 
that a wide variety of cells including fibroblasts, 
myoblasts, macrophages, platelets, and leukocytes 
express RGD-directed receptors with considerable 
homology (reviewed in [27]). 
In spite of the rapid progress in the field of cell 
adhesion, little information is available on sFN of 
macrophages, and we have investigated its quanti- 
ty. In the present study, a key technque which 
enabled us to estimate the quantity of sFN on the 
macrophage monolayer was the limited trypsiniza- 
tion of the monolayer surface. It efficiently re- 
moved sFN from the cell surface, but did not 
appear to impair FN receptor activity. However, 
there are conflicting reports as to the trypsin sen- 
sitivity of FN receptors on cells. FN receptors on 
human monocytes [5] and rat peritoneal 
macrophages [7] have been reported to be trypsin 
sensitive, but those on fibroblastic cells have been 
reported to be trypsin resistant [28,29]. These dif- 
ferences may be due not only to the difference in 
the cell type but to the differences in the conditions 
of the enzyme treatment. 
Data on the binding of ‘*‘I-pFN to the trypsin- 
ized macrophages also made it possible to estimate 
the total capacity of the cells to bind FN. The 
amount of saturation binding of 1251-pFN (6.3 /cg 
per lo6 cells) approximates to the total capacity of 
the cells. The number of FN receptors calculated 
from this value is approx. 5 x lo6 per cell assuming 
1: 1 binding of. pFN and FN receptor. A Scatchard 
plot of the binding data, however, did not give a 
linear line which would allow us to estimate 
binding constant and the receptor number. Accor- 
ding to Hormann and Jelinic [30], there are ap- 
prox. lo6 FN receptor sites per cell with weak 
affinity and approx. lo4 sites per cell with high af- 
finity on trypsinized guinea pig peritoneal 
macrophages in suspension. However, no satura- 
tion of FN binding was attained in their ex- 
periments. The number of FN receptors in 
fibroblastic cell suspensions was reported to be 5 x 
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10’ per cell. The variation of cells and the dif- 
ference in the conditions of the binding ex- 
periments may be reflected in these results. 
It is likely that a considerably large fraction of 
the FN receptors on the surface of thioglycollate- 
induced mouse peritoneal macrophages is covered 
with sFN since the amount of sFN appears to be as 
much as 60% of the maximal binding capacity of 
the macrophage monolayer. sFN may be their own 
product since macrophages and differentiated 
monocytes produce FN [13,3 1,321 although the 
possibility that the sFN is derived from ascites 
fluid or plasma cannot be excluded. 
sFN on the macrophages has been suggested to 
be involved in some of their functions. Remold et 
al. [12] reported the involvement of an FN-like 
component of the peritoneal macrophage surface 
in the response of macrophages to a migration in- 
hibitory factor. We have previously reported that 
mouse peritoneal macrophages recognize ox- 
idatively damaged erythrocytes [33], and recently 
found that sFN on the macrophages plays a pro- 
moting role in the recognition of the oxidatively 
damaged erythrocytes (manuscript in preparation). 
These observations indicate that effects of sFN on 
macrophages have to be taken into consideration 
in studying the effects of extracellular FN on 
macrophage functions. 
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